Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,506.48
(
-1.51%
)
US TECH 100
23,484.80
(
-0.99%
)
Dow Jones
45,577.47
(
-0.96%
)
Brent Oil
105.10
(
0.00%
)
Bitcoin
69,170.85
(
0.41%
)
News Focus
News Focus
Post# of 257268
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (3) Keep Next 10 Report Keyboard Shortcuts
Replies (3) Next 10 Prev Next

caravon

Send PM Follow Ignore
Followers 12
Posts 1058
Boards Moderated 0
Alias Born 02/21/2007

caravon

Re: oc631 post# 171461

Wednesday, 12/18/2013 10:34:51 AM

Wednesday, December 18, 2013 10:34:51 AM

Post# of 257268

The bearish argument against ABBV is that with these results they do not have a credible "natural" positioning strategy in the market



I will not sell Abbott short regarding to marketing. Abbott has an outstanding marketing expertise and capabilities. With all these numbers coming from HCV trials, the marketing will be the key.
Public Reply Private Reply New Post
Keep Last Read
Replies (3) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (3) Next 10 Prev Next

Unleash the power of Level 2

Spot liquidity moves with access to US order books.

Sign Up